JPMorgan Downgrades Infinity Pharmaceutical (INFI) to Underweight

November 12, 2018 5:39 AM EST Send to a Friend
JPMorgan analyst Anupam Rama downgraded Infinity Pharmaceutical (NASDAQ: INFI) ...

This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE

Member Login